+

WO2009033812A3 - Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent - Google Patents

Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent Download PDF

Info

Publication number
WO2009033812A3
WO2009033812A3 PCT/EP2008/008156 EP2008008156W WO2009033812A3 WO 2009033812 A3 WO2009033812 A3 WO 2009033812A3 EP 2008008156 W EP2008008156 W EP 2008008156W WO 2009033812 A3 WO2009033812 A3 WO 2009033812A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
combination
phe
msh
neuropeptide
Prior art date
Application number
PCT/EP2008/008156
Other languages
French (fr)
Other versions
WO2009033812A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009033812A2 publication Critical patent/WO2009033812A2/en
Publication of WO2009033812A3 publication Critical patent/WO2009033812A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the peptide compounds Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 and Ac-Ser-Tyr-Ser-Met-Glu- His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008156 2007-09-11 2008-09-09 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent WO2009033812A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017764 2007-09-11
EP07017748 2007-09-11
EP07017748.0 2007-09-11
EP07017764.7 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033812A2 WO2009033812A2 (en) 2009-03-19
WO2009033812A3 true WO2009033812A3 (en) 2009-05-22

Family

ID=40374301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008156 WO2009033812A2 (en) 2007-09-11 2008-09-09 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009033812A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206642A1 (en) * 2009-10-15 2011-08-25 Cohava Gelber Preventing obesity-related metabolic syndrome with melagonesis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056353A2 (en) * 1999-03-24 2000-09-28 Zengen Inc. A uro-genital condition treatment system
WO2001017958A2 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Neuropeptide sf receptor assays, compounds and therapeutic methods
WO2001082953A2 (en) * 2000-05-02 2001-11-08 Action Pharma Aps Methods for treatment of diseases associated with inflammation under non-ischemic conditions
WO2007067519A2 (en) * 2005-12-06 2007-06-14 Ophthalmic Research Associates, Inc. The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056353A2 (en) * 1999-03-24 2000-09-28 Zengen Inc. A uro-genital condition treatment system
WO2001017958A2 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Neuropeptide sf receptor assays, compounds and therapeutic methods
WO2001082953A2 (en) * 2000-05-02 2001-11-08 Action Pharma Aps Methods for treatment of diseases associated with inflammation under non-ischemic conditions
WO2007067519A2 (en) * 2005-12-06 2007-06-14 Ophthalmic Research Associates, Inc. The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

Also Published As

Publication number Publication date
WO2009033812A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
LTPA2017015I1 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
EA201201400A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF AUTOIMMUNE AND OTHER DISEASES
HK1126427A1 (en) Low-dose rapamycin for the treatment of vascular permeability-related diseases
IL184125A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
WO2012061390A3 (en) Therapeutic compositions and methods
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2010065563A3 (en) Apratoxin therapeutic agents: mechanism and methods of treatment
WO2008051421A3 (en) Peptide-cytotoxic conjugates
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009033812A3 (en) Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802621

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802621

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载